<DOC>
	<DOCNO>NCT00556452</DOCNO>
	<brief_summary>The goal study ( Phase I ) determine appropriate dose Clofarabine Busulfan full-intensity conditioning ( Clo/BU4 regimen ) prior transplant ( Phase II ) investigate safety effectiveness regimen condition stem cell transplant treatment aggressive hematologic malignancy subject conventional approach fail .</brief_summary>
	<brief_title>Study Stem Cell Transplantation Hematologic Malignancies Using Clofarabine Busulfan Regimen</brief_title>
	<detailed_description>Transplants stem cell collect blood unrelated donor ( allo-HSCT ) use commonly many blood cancer curable conventional method chemotherapy . Although allo-HSCT great potential , still high risk due infection , graft-versus-host disease ( GVHD ) , donor 's cell attack recipient 's tissue foreign , due toxic effect chemotherapy drug give prepare ( condition ) recipient 's bone marrow transplant . As reduced intensity conditioning , combination Fludarabine low dose Busulfan ( Flu/BU2 ) one popular regimen . Among full-intensity regimen , combination Fludarabine standard-dose Busulfan ( Flu/BU4 ) investigate recently show well tolerate . Clofarabine , similar Fludarabine , know strong anti-tumor effect Fludarabine show promise treat aggressive acute leukemia . In addition , evidence well-tolerated manageable side effect especially old subject . Thus replace Fludarabine Clofarabine full-intensity transplant regimen , Clo/BU4 may provide regimen increase anti-tumor activity without add significant risk toxicity . The goal study ( Phase I ) determine appropriate dose Clofarabine Busulfan full-intensity regimen ( Clo/BU4 ) ( Phase II ) investigate safety effectiveness regimen condition HSCT treatment aggressive hematologic malignancy , subject conventional approach fail .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<mesh_term>Clofarabine</mesh_term>
	<mesh_term>Busulfan</mesh_term>
	<criteria>Disease Criteria Acute leukemia chronic myelogenous leukemia blastic crisis accelerate phase , remission time transplant Myelodysplastic syndrome , 5 % blast bone marrow time transplant Hodgkin NonHodgkin Lymphomas : Not CR PET scan CT scan transplant , relapse within 1 year previous remission CLL remission Multiple Myeloma , remission Suitable donor available ( related unrelated ) Age , Organ Function Criteria Age : ≤ 70 year Cardiac : LV Ejection Fraction ≥ 40 % MUGA Echocardiogram Pulmonary : FEV1 FVC ≥ 40 % predict , DLCO ( correct hemoglobin ) ≥ 40 % predict Renal : Adult population : serum creatinine ≤ 1.0 mg/dL ( serum creatinine &gt; 1.0 mg/dL , estimate glomerular filtration rate ( GFR ) must &gt; 60 mL/min/1.73 m2 calculate Modification Diet Renal Disease equation ) Renal : Pediatric population : serum creatinine clearance ≥ 90 ml/min/1.73 m2 calculate Schwartz formula estimate GFR Hepatic : serum total bilirubin ≤ 2.0 mg/dl AST / ALT ≤ ULN x 4 Performance status : Karnofsky ≥ 70 % Other active lifethreatening cancer require treatment alloHSCT HIV1 HIV2 positive Uncontrolled medical psychiatric disorder Uncontrolled viral fungal infection Active CNS leukemia Noncompliant medications No appropriate caregiver identify</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>January 2015</verification_date>
</DOC>